Measurement of serum tenascin-X in patients with congenital adrenal hyperplasia at risk for Ehlers-Danlos contiguous gene deletion syndrome CAH-X
- PMID: 31666125
- PMCID: PMC6820911
- DOI: 10.1186/s13104-019-4753-7
Measurement of serum tenascin-X in patients with congenital adrenal hyperplasia at risk for Ehlers-Danlos contiguous gene deletion syndrome CAH-X
Abstract
Objective: Approximately 10% of patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency carry a mutation that disrupts CYP21A2 and the flanking TNXB gene resulting in CAH-X, a contiguous gene deletion syndrome. TNXB encodes tenascin-X (TNX), an extracellular matrix glycoprotein that plays an important role in collagen organization. TNXB impairment is associated with Ehlers-Danlos syndrome. Symptoms include joint hypermobility, hernias and cardiac defects. We measured serum TNX using an antibody targeting the amino-terminal of the TNX protein in 161 subjects, including extensively genotyped and phenotyped CAH patients, their relatives, and healthy controls.
Results: We evaluated the potential of serum TNX as a screening tool for CAH-X. CAH-X patients, especially haploinsufficient patients carrying the TNXA-TNXB chimeric gene CAH-X-CH-1 showed reduced TNX levels compared to controls (P < 0.05). TNX levels were similar in all subjects carrying a TNXB mutation. However, CAH patients who did not harbor a TNXB mutation also had reduced TNX compared to controls (P < 0.001). Thus, measuring serum TNX is not an effective screen for CAH-X amongst patients with CAH. TNXB genotyping is recommended for CAH patients who have symptoms of a connective tissue disorder. Epigenetic factors that influence TNX expression require further study.
Keywords: CYP21A2; Congenital adrenal hyperplasia; Ehlers–Danlos syndrome; TNXB; Tenascin-X.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures


Similar articles
-
A TNXB splice donor site variant as a cause of hypermobility type Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia.Mol Genet Genomic Med. 2021 Feb;9(2):e1556. doi: 10.1002/mgg3.1556. Epub 2020 Dec 17. Mol Genet Genomic Med. 2021. PMID: 33332743 Free PMC article.
-
Tenascin-X haploinsufficiency associated with Ehlers-Danlos syndrome in patients with congenital adrenal hyperplasia.J Clin Endocrinol Metab. 2013 Feb;98(2):E379-87. doi: 10.1210/jc.2012-3148. Epub 2013 Jan 2. J Clin Endocrinol Metab. 2013. PMID: 23284009 Free PMC article.
-
Broadening the Spectrum of Ehlers Danlos Syndrome in Patients With Congenital Adrenal Hyperplasia.J Clin Endocrinol Metab. 2015 Aug;100(8):E1143-52. doi: 10.1210/jc.2015-2232. Epub 2015 Jun 15. J Clin Endocrinol Metab. 2015. PMID: 26075496 Free PMC article.
-
Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome.Horm Res Paediatr. 2018;89(5):352-361. doi: 10.1159/000481911. Epub 2018 May 7. Horm Res Paediatr. 2018. PMID: 29734195 Free PMC article. Review.
-
Congenital Adrenal Hyperplasia and Ehlers-Danlos Syndrome.Front Endocrinol (Lausanne). 2022 Feb 25;13:803226. doi: 10.3389/fendo.2022.803226. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35282436 Free PMC article. Review.
Cited by
-
DNA Methylation in Babies Born to Nonsmoking Mothers Exposed to Secondhand Smoke during Pregnancy: An Epigenome-Wide Association Study.Environ Health Perspect. 2021 May;129(5):57010. doi: 10.1289/EHP8099. Epub 2021 May 19. Environ Health Perspect. 2021. PMID: 34009014 Free PMC article.
-
Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X.Genes (Basel). 2023 Jan 19;14(2):265. doi: 10.3390/genes14020265. Genes (Basel). 2023. PMID: 36833192 Free PMC article.
-
Ehlers-Danlos Syndrome in the Field of Psychiatry: A Review.Front Psychiatry. 2022 Jan 11;12:803898. doi: 10.3389/fpsyt.2021.803898. eCollection 2021. Front Psychiatry. 2022. PMID: 35087434 Free PMC article. Review.
References
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous